EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study

Melissa Bolier iD, Demi T C de Winter, Vincent G Pluimakers, Marta Fiocco, Sjoerd A A van den Berg, Dorine Bresters, Eline van Dulmen-den Broeder, Margriet van der Heiden-van der Loo, Imo Höfer, Geert O Janssens, Leontien C M Kremer, Jacqueline J Loonen und 9 weitere

Cancer · 2025-01 · 131 (1)

DOI: 10.1002/cncr.35681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 02.01.2025. Verfasst von Melissa Bolier und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Endocrinology Section, Erasmus Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Metabolic Syndrome, Cancer Survivors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting Kinderen Kankervrij, KiKaRoW, ODAS Stichting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Because the occurrence of metabolic syndrome (MetS) might contribute to childhood cancer survivor’s excess risk of cardiovascular disease, the authors assessed the prevalence and determinants of MetS in the Dutch Childhood Cancer Survivor Study (DCCSS‐LATER2) cohort.

Methods

In total, 2338 adult childhood cancer survivors (CCS) were cross‐sectionally assessed for the prevalence of MetS, using the Lifelines cohort ( N = 132,226 adults without a history of cancer) as references. The prevalence of MetS was clinically assessed using existing classifications, as well as an alternative method using dual‐energy x‐ray absorptiometry fat% instead of waist circumference to define abdominal adiposity. Logistic regression models, adjusted for age and sex, were used to investigate the association between the presence of MetS and both cohorts. Demographic, lifestyle, and treatment determinants of MetS were identified through multivariable logistic regression.

Results

The survivor cohort (median age, 34.7 years, median follow‐up time, 27.1 years) showed increased adjusted odds ratio (aOR) for MetS (modified National Cholesterol Education Program Adult Treatment Panel III criteria), as compared to the reference cohort (aOR, 2.07; 95% confidence interval [CI], 1.85–2.32). Compared to these criteria, the alternative method identified 57 additional survivors with MetS (395 of 2070 [19.1%] vs. 452 of 1960 [23.1%], respectively). Age (odds ratio [OR], 1.07; 95% CI, 1.04–1.10, per year increase), smoking (OR, 1.46; 95% CI, 1.04–2.04), low physical activity (OR, 1.48; 95% CI, 1.05–2.09), abdominal radiotherapy (OR, 2.13; 95% CI, 1.01–4.31; >30 Gy), cranial radiotherapy (OR, 2.89; 95% CI, 1.67–4.96; 1–25 Gy; and OR, 2.44; 95% CI, 1.30–4.47; >25 Gy), total body irradiation (OR, 6.17; 95% CI, 3.20–11.76), and underlying central nervous system tumor (OR, 1.78; 95% CI, 1.21–2.60) were associated with MetS.

Conclusion

The high risk of MetS in CCS, combined with several potential modifiable factors, underscores the need for timely identification and intervention strategies to mitigate the long‐term cardiovascular risks in CCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeCancer SurvivorsHumansMaleFemaleAdultPrevalenceNetherlandsCross-Sectional StudiesNeoplasmsChildYoung AdultAdolescentMiddle AgedRisk Factors

Stichwörter der Autor:innen

childhood cancer survivorlate effectsmetabolic syndromesurvivorship

Autor:innen und Institutionen

  • Department of Internal Medicine, Endocrinology Section, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Biomedical Data Science, Medical Statistics Section, Leiden University Medical Center, Leiden, The Netherlands.
  • Mathematical Institute Leiden University, Leiden, The Netherlands.
  • Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Pediatric Oncology, Cancer Center Amsterdam, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Melissa Bolier

Förderung

  • Stichting Kinderen Kankervrij
  • KiKaRoW
  • ODAS Stichting

Zitieren

APA

Bolier, M., de Winter, D. T. C., Pluimakers, V. G., Fiocco, M., van den Berg, S. A. A., Bresters, D., van Dulmen-den Broeder, E., van der Heiden-van der Loo, M., Höfer, I., Janssens, G. O., Kremer, L. C. M., Loonen, J. J., Louwerens, M., van der Pal, H. J., Pluijm, S. M. F., Tissing, W. J. E., van Santen, H. M., de Vries, A. C. H., van der Lely, A. J., …, & Neggers, S. J. C. M. M. (2025). Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study. Cancer, 131(1). https://doi.org/10.1002/cncr.35681

Vancouver

Bolier M, de Winter DTC, Pluimakers VG, Fiocco M, van den Berg SAA, Bresters D, et al. Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study. Cancer. 2025;131(1). doi:10.1002/cncr.35681

BibTeX
@article{Bolier2025,
  author = {Bolier, Melissa and de Winter, Demi T C and Pluimakers, Vincent G and Fiocco, Marta and van den Berg, Sjoerd A A and Bresters, Dorine and van Dulmen-den Broeder, Eline and van der Heiden-van der Loo, Margriet and Höfer, Imo and Janssens, Geert O and Kremer, Leontien C M and Loonen, Jacqueline J and Louwerens, Marloes and van der Pal, Heleen J and Pluijm, Saskia M F and Tissing, Wim J E and van Santen, Hanneke M and de Vries, Andrica C H and van der Lely, Aart-Jan and van den Heuvel-Eibrink, Marry M and Neggers, Sebastian J C M M},
  title = {Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {1},
  doi = {10.1002/cncr.35681}
}
Kostenlos starten →